Chang Chi-Jen, Ko Po-Jen, Hsu Lung-An, Ko Yu-Shien, Ko Yu-Lin, Chen Chin-Fen, Huang Chiu-Ching, Hsu Tsu-Shiu, Lee Ying-Shiung, Pang Jong-Hwei S
First Cardiovascular Division, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan.
Am J Kidney Dis. 2004 Jan;43(1):74-84. doi: 10.1053/j.ajkd.2003.09.015.
The effect of percutaneous transluminal angioplasty (PTA) in the treatment of hemodialysis vascular access stenosis is attenuated by a high restenosis rate, which results mainly from neointimal hyperplasia. Cellular proliferation is one of the most important biological mechanisms involved in neointimal hyperplasia and may be a potential target of intervention to prevent restenosis.
We investigated the activity of cellular proliferation of restenotic lesions by means of immunohistochemistry, using an antibody to the proliferating cell nuclear antigen. Specimens from 10 primary stenotic and 20 restenotic lesions of 30 Brescia-Cimino fistulae were obtained during revision.
The proliferation index of the restenotic group was strikingly significantly greater than that of the primary stenotic group (intima, P < 0.001; media, P = 0.001). Proliferation indices of patients with diabetes in the restenotic group were significantly higher than those of patients without diabetes (intima, P = 0.028; media, P = 0.002). In the restenotic group, proliferation indices correlated negatively with the interval from PTA to restenosis (intima, r = -0.741; P < 0.001; media, r = -0.589; P = 0.006) and positively with the number of PTAs per lesion (intima, r = 0.754; P < 0.001; media, r = 0.506; P = 0.004).
We show markedly high cellular proliferation activity in early restenotic lesions of arteriovenous fistulae. These findings indicate that adjunctive antiproliferative therapy is mandatory in preventing restenosis after PTA, especially in patients with diabetes.
经皮腔内血管成形术(PTA)治疗血液透析血管通路狭窄的效果因再狭窄率高而减弱,而再狭窄主要是由新生内膜增生导致的。细胞增殖是新生内膜增生所涉及的最重要生物学机制之一,可能是预防再狭窄的潜在干预靶点。
我们采用增殖细胞核抗原抗体,通过免疫组织化学方法研究再狭窄病变的细胞增殖活性。在修复过程中获取了30个布雷西亚 - 奇米诺内瘘的10个原发性狭窄病变和20个再狭窄病变的标本。
再狭窄组的增殖指数显著高于原发性狭窄组(内膜,P < 0.001;中膜,P = 0.001)。再狭窄组中糖尿病患者的增殖指数显著高于非糖尿病患者(内膜,P = 0.028;中膜,P = 0.002)。在再狭窄组中,增殖指数与PTA至再狭窄的间隔呈负相关(内膜,r = -0.741;P < 0.001;中膜,r = -0.589;P = 0.006),与每个病变的PTA次数呈正相关(内膜,r = 0.754;P < 0.001;中膜,r = 0.506;P = 0.004)。
我们发现动静脉内瘘早期再狭窄病变中细胞增殖活性明显较高。这些发现表明,在预防PTA后再狭窄方面,尤其是糖尿病患者,辅助抗增殖治疗是必不可少的。